Studies whether flozin drugs help prevent kidney injury from contrast dye
Observes flozin use and kidney injury after heart procedures with contrast dye in adults.
Plain-language title generated from the registry record
Registry title: Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI
Key facts
- Where
- Bydgoszcz, PolandSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who had coronary angiography or a stent procedure (PCI) with contrast dye. It studies whether flozin drugs protect the kidneys.
- Age
- 18 Years and older
- Sex
- All sexes
- Earlier treatment
- Had coronary angiography or PCI during the study period.
- Biomarker or test result
- Blood creatinine measured both before and after the procedure.
Main reasons for not taking part
- Needed data for the analysis are missing
- Contrast dye volume under 50 mL
- Contrast dye volume over 500 mL
Read by machine on 12 November 2026.
Where in Poland
- Collegium Medicum w BydgoszczyBydgoszcz, PolandContact: Piotr Niezgoda, MD, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Collegium Medicum w Bydgoszczy
- Trial code
- NCT07231939
- Record updated
- 17 November 2025
- Original description
All consecutive patients hospitalized from 01.01.2020 to 30.09.2025 who underwent coronary angiography or PCI will be eligible for inclusion.Read full original descriptionShow less
FLOzins for pREveNtion of Contrast-inducEd Acute Kidney Injury (FLORENCE) Study
All consecutive patients hospitalized from 01.01.2020 to 30.09.2025 who underwent coronary angiography or PCI will be eligible for inclusion.
The final analysis will be limited to individuals in whom the volume of ICM administered during the index procedure was between 50 and 500 mL and for whom both pre- and post-procedure serum creatinine measurements were available.
The primary objective of the study is the effect of short-term and long-term SGLT2i therapy on the occurrence of CI-AKI in patients undergoing diagnostic or therapeutic procedures with ICM.
Inclusion: all consecutive patients who underwent PCI or coronary angiography during the study period for whom the variables required for the analysis are available.
Exclusion: unavailability of variables required for the analysis, volume; contrast agent volume <50 mL or >500 mL.